Zymeworks (NASDAQ:ZYME) announced on June 10, 2024, that China's National Medical Products Administration (NMPA) has accepted its biologics license application (BLA) for zanidatamab.

The application, in collaboration with BeiGene, targets second-line treatment of HER2-positive biliary tract cancer (BTC).

With this acceptance, Zymeworks is set to receive an $8 million milestone payment.

The BLA's acceptance follows the U.S. FDA's priority review grant for zanidatamab in May 2024, with an expected action date of November 29, 2024.